On April 28, 2026, Damora Therapeutics, Inc. announced the departure of Chief Financial Officer Lori Firmani effective May 1, 2026, and appointed Brian Burkavage as the new CFO. Firmani will receive a lump sum for salary continuation, a $6,000 health savings contribution, and accelerated equity awards.